Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L, Hecker JS, Rothenberg-Thurley M, Rivière J, Jentzsch M, Ksienzyk B, Buck MC, van der Garde M, Fischer L, Winter S, Rauner M, Tsourdi E, Weidner H, Sockel K, Schneider M, Kubasch AS, Nolde M, Hausmann D, Lützner J, Goralski S, Bassermann F, Spiekermann K, Hofbauer LC, Schwind S, Platzbecker U, Götze KS, Metzeler KH. Hartmann L, et al. Among authors: gotze ks. Leukemia. 2022 Nov;36(11):2647-2655. doi: 10.1038/s41375-022-01700-3. Epub 2022 Sep 21. Leukemia. 2022. PMID: 36131041 Free PMC article.
SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J. Leischner H, et al. Blood. 2012 Apr 26;119(17):4026-33. doi: 10.1182/blood-2011-07-365726. Epub 2012 Mar 12. Blood. 2012. PMID: 22411868 Free article.
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Braulke F, et al. Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25. Leuk Res. 2013. PMID: 23623559 Clinical Trial.
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A. Platzbecker U, et al. Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. Leukemia. 2014. PMID: 24186004 Clinical Trial. No abstract available.
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U. Neukirchen J, et al. Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26. Leuk Res. 2014. PMID: 24238640
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.
Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS, Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U, Brümmendorf TH. Beier F, et al. Among authors: gotze ks. Leuk Res. 2015 Sep 21:S0145-2126(15)30380-5. doi: 10.1016/j.leukres.2015.09.003. Online ahead of print. Leuk Res. 2015. PMID: 26427727
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U. Schuler E, et al. Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. Leukemia. 2016. PMID: 26668126 Clinical Trial. No abstract available.
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann WK, Germing U, Nolte F. Mossner M, et al. Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2. Leukemia. 2016. PMID: 27133825 Clinical Trial. No abstract available.
167 results